tbuckley/cabot-search huggingface dataset:
Category Index
Journal: Hepatology (2012)

novel microRNA 33a-mediate 725 Analysis of the Contribution 724 Bile Salt Kinetics in Childr 35 Circulating bile acids may d 36 Expression and targeting of 732 Fenofibrate, a specific pero 731 Fibroblast growth factor (FG 727 Genetic variation in ABCG5/8 729 Norursodeoxycholic Acid Coun 726 Primary bile salts different 730 The Nrf2 activator oltipraz 728 The bile acid receptor TGR5 723 Cholangiocyte Biology A frequent PNPLA3 variant pr 288 Bile acid-mediated release o 31 Cyclic-AMP-dependent, Rac1-m 118 Cytokines regulate biliary s 34 Genetic Loss of Muscarine-3 289 HDAC6 is overexpressed in cy 290 Mechanosensitive pathways in 293 MicroRNA506 (mIR506) downreg 295 PDX-1/Hes-1 interaction is a 32 Reduced FGF19 level in bile 292 Reduced melatonin synthesis 294 Regulation of Apico-basal Po 291 Activation of the farnesoid 1263 Cyclin E1, but not Cyclin E2 104 Decreased Nuclear Receptor A 244 Elucidating the functional r 1252 Estrogen exhibits dual roles 1251 Factor VII Expression is a C 1259 Functional consequences of W 1256 HCV induces hepatocyte TGF-1260 Hepatocellular Endocytic Rec 243 Lack of Nrf2 Delays Hepatocy 1258 Loss of Cyclin E1 attenuates 1253 Novel sex-differential Retin 105 Nrf2 Deficiency Impairs Mate 1262 Oncogenic CCRK is an integra 103 Ontogenic Profiling of the N 1264 Phosphatidylcholine Transfer 1261 Regulation of the Wnt/β-cat 1255 Rosiglitazone reduces
inSIRT trial: Single-center phase II study of yttrium-90 radioactive resin microspheres in the treatment of liver-predominant metastatic colorectal adenocarcinoma after failure of first-line combination chemotherapy.
Authors: Eric Roeland, Kelly Anne Shimabukuro, Paul Timothy Fanta, Steven C. Rose, Tony R. Reid
Journal: Journal of Clinical Oncology (2012)

685 Background: Liver metastases develop in half of colorectal cancer (CRC) cases and once metastatic ~90% die due to consequences from the hepatic metastases. We are evaluating the aggressive management of liver metastases through the incorporation of selective internal radiation therapy (SIRT) using yttrium-90 radioactive microspheres after evidence of progressive disease following first-line FOLFOX ± bevacizumab. Optimal timing for microsphere treatment relative to chemotherapy is not clearly established. We present preliminary data of a phase II study evaluating tumor response rates to SIRT following FOLFOX ± bevacizumab and prior to FOLFIRI. Methods: Subjects with predominant hepatic metastatic CRC despite first-line FOLFOX based therapy ± bevacizumab are eligible. Interventional radiology and nuclear medicine assess the liver lesions and the subject receives SIRT followed by second-line FOLFIRI (without bevacizumab) 4-6 weeks after the final SIRT. The primary objective is PFS at 6 mos and secondary objectives include: OS, tumor response rates, and toxicity. Results: To date, 8 metastatic CRC subjects have been treated and 9 subjects enrolled (goal 30 subjects). One subject was withdrawn due to progressive lung metastases. 4 of 8 subjects (50%) achieved PFS at 6 mos and average TTP is 6.7 mos (0.7-17.3 mos). Overall treatment has been well tolerated, but one possible study related SAE of liver failure occurred (subject 8). The OS endpoint has not been achieved. Conclusions: Historically, second-line FOLFIRI has achieved a 2.5 mos median PFS. In 8 subjects with liver predominant metastatic CRC, we have observed 50% PFS at 6 mos. These encouraging results demonstrate the utility of an innovative direct approach to metastatic CRC after failure of first-line combination chemotherapy. [Table: see text]
Scientific session
Authors: S Kornfeld, E Brigino, R Haire, S Strong, H Tang, S Sung, S Fu, G Litman, St Petersburg, Fl Charlottesville, P Barros-Nunes, A Nagao, I Douglas, D So16, C Naspitz, L Leiva, K Baker, " Merida, San Antonio, M Gutierrez, R Mann, R Harbeck, J Routes, Digeorge Syndrome, C Smith, S Douglas, J Greene, T Brown, K Sullivan, D Amran, C Underhill, M Stein, Ribomunyl Lester, H Gillanders, R Hanson, T Rubocki, St Hansen, ; Louis, A Toubert, F Boisg6rault, V Tieng, N Dulphy, M Stolzenberg, R Tamouza, G Burrows, K Ariail, B Celnik, J Gambee, H Offner, A Vandenbark, Mouse Cd, J Maher, O Naidenko, R Modlin, M Kronenberg, Los Angeles, Y Ohshima, Y Tanaka, G Delespesse, R Mouawad, C Soubrane, E Antoine, M Gozy, P Boyle, F Durda, J Pandolfi, Ma Charlestown, M Kaji, M Kobayashi, R Pollard, F Suzuki, G Senaldi, C Shaklee, M Kondo, K Akashi, K Sugamura, I Weissman, A Blum, A Metwali, D Elliott, J Li, M Sandor, R Lynch, J Weinstock, Iowa City, Ia Madison, R Suenaga, M Evans, V Rider, N Abdou, Kansas City, M Mice, V Maldonado, G Kakkanaiah, F Macdonald, E Chen, W Balish, B Farkas, P Kotzin, R Cohen, Pa Eisenberg, S Chen, Y Takeoka, L Pike-Nobile, A Ansari, R Boyd, K Ohtsuka, M Stimmler, D Horwitz, N Rothfield, D V~quez-Abad, V Monteon, J-L Senecal, S Walsh, A Stitzel, M Satoh, K Hamilton, H Richards, P Wooley, M Elloitt
Journal: Journal of Allergy and Clinical Immunology (1997)
British Journal of Dermatology, London
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intern
Authors: S. Ryan Gregory
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I evaluation of tipifarnib in combination with low dose Ara-C (LDAC) in high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): final results
Authors: E. J. Feldman, D. Douer, W. Walsh, V. M. Moyo, J. E. Cortes
Journal: Journal of Clinical Oncology (2008)

14531 Background: Tipifarnib (T) is a farnesyltransferase inhibitor with clinical activity in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Low dose Ara-C (LDAC) has utility in the elderly with MDS/AML; hence its use in combination with investigational agent T to improve outcomes is warranted. Methods: Objectives of this phase I, dose-finding, multicenter, open-label study were to determine the maximum tolerated dose (MTD) of T+LDAC observed during the first 28 day cycle and assessment of preliminary activity and safety of T+LDAC at the MTD level. MDS (IPSS Int 1, 2 or High) and untreated AML pts (age≥75y or≥65y with preceding MDS) or relapsed/refractory AML (age>18y) were included. A traditional 3+3 dose-escalation was used. T(Dose Level 0) was administered initially at 200mg PO BIDx21/28 days in combination with LDAC 10mg SC BIDx10/28 days. Efficacy was assessed by bone marrow and peripheral blood count studies. Results: 31 pts were enrolled and included: 5 MDS (Int 1 n=1, Int 2 n=1, High n=3) and 26 AML (11/26 pts with no previous therapy); 31 pts were evaluable. Mean baseline characteristics for the entire cohort were: age 73y, 74% men, Hb 9.63± 1.15g/dL, WBC 8.33± 11.73 103/μL, platelets 98.35± 132.67 103/μL. The observed DLT for T+LDAC was generalized rash seen at Dose Level 3. The MTD was therefore determined to be T 300mg and LDAC 15mg. Efficacy results are shown below. The most common grade 3/4 adverse events were neutropenia, thrombocytopenia, anemia rash, and pyrexia. Conclusions: These final results show the combination of T at 300mg PO BID×21 days and LDAC at 15mg SC BID×10 days to be the MTD in this study. Preliminary safety and efficacy results at this dose level warrant further studies with this regimen in this patient population. Table Measure of Efficacy All Comers (n=31) MTD Cohort (n=19) Complete response, n(%) 4(13%) 3(16%) Partial Response, n(%) 1(3%) 1(5%) Hematologic improvement, n(%) 0(0%) 0(0%) Stable Disease (SD), n(%) 7(23%) 4(21%) Disease Progression, n(%) 9(29%) 5(26%) Response Not Assessed, n(%) 10(32%) 6(32%) Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Ortho Biotech Ortho Biotech Ortho Biotech Ortho Biotech
Joint study of extracranial arterial occlusion as a cause of stroke. I. Organization of study and survey of patient population
Authors: W. S. Fields
Journal: JAMA (1968)

Between July 1, 1961, and June 30, 1965, 4,748 patients with signs and symptoms of ischemic cerebrovascular disease were admitted to various institutions for prospective investigation. The mean age for the group was 60 years. Two thirds were below 65 years of age. A significantly larger proportion of nonwhites were in the age group below 55. Eighty-four percent were white, and men outnumbered women 2:1. Interinstitutional differences in clinical status of patients were noted, particularly between vascular surgical and neurologic services. Complete arteriographic studies showing intracranial and extracranial circulation were accomplished in 80%. Twenty-five percent of the patients had no lesions demonstrated or had surgically inaccessible lesions only. The remainder had surgically accessible lesions, both with or without inaccessible lesions. A higher proportion of patients with surgically accessible lesions was noted among whites.
International Conference on Magnetic Resonance in Cancer
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article International Conference on Magnetic Resonance in Cancer Get access JNCI: Journal of the National Cancer Institute, Volume 73, Issue 6, December 1984, Page 1491, https://doi.org/10.1093/jnci/73.6.1491-e Published: 01 December 1984
VIENNA
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tomlinson report.
Authors: S Dische
Journal: BMJ (1993)

Had our awareness of this problem not been increased by the first case the diagnosis in the second case might well have been delayed.This is an important diagnosis to consider as rhabdomyolysis can lead to acute renal failure associated with myoglobinuria.2In both patients adequate hydration was maintained, and neither developed myoglobinuria even though the creatine kinase concentration in the patient of normal build reached a peak of 20 000 IUll.In the light of our experience we now consider misuse of anabolic steroids as part of our differential diagnosis for atypical chest pain in all young people, not just those with an extremely muscular build.
Lithium prophylaxis of corticotropin-induced psychosis
Authors: W. E. Falk
Journal: JAMA (1979)

Corticotropin is one of the few accepted treatments for acute exacerbations of multiple sclerosis and retrobulbar neuritis. Psychosis is a serious side effect usually necessitating discontinuation of the drug therapy. Because mood disorders preponderated in most patients previously described with this psychosis, 27 patients were empirically treated with lithium carbonate concurrently with corticotropin. In none of the patients treated with lithium did a psychotic reaction occur, although in a comparable group of 44 patients previously treated identically with corticotropin but without lithium, six (14%) became psychotic. (<i>JAMA</i>241:1011-1012, 1979)
Scanning malignant neoplasms with gallium 67
Authors: C. L. Edwards
Journal: JAMA (1970)

Gallium has an affinity for some human as well as animal neoplasms. Carrier-free gallium citrate Ga 67 administered intravenously is localized in a variety of malignant tumors that can then be detected on scintiscans. Nonosseous as well as skeletal lesions can be seen, including some that are not otherwise detectable. No untoward effects were observed in 41 patients studied. Scans were abnormal in 23 patients with a variety of malignant neoplasms; reticulum cell sarcoma, lymphoblastoma, and poorly differentiated adenocarcinoma gave the most consistent results. The 18 patients in whom scans were normal included three patients with plasma cell myeloma, four with lymphocytoma, and five with Hodgkin's disease involving small retroperitoneal nodes. Gallium localization is greatest in viable tumor, less in fibrotic or necrotic tumor, and diminished by irradiation and effective chemotherapy. The mechanism is unknown.
International Comments
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Saving asthmatics.
Authors: A R Luksza
Journal: BMJ (1979)

The tyrosine kinase inhibitor sunitinib was recently approved for use against gastrointestinal stromal tumors and advanced renal cell carcinoma. Yet, the protective effect of sunitinib against breast cancer has been poorly investigated. In this study, we investigated the antiproliferative and apoptogenic effects of sunitinib and the possible mechanism involved against the MCF7 human breast cancer cell line. Treatment of MCF7 cells with sunitinib caused concentration-dependent cell growth suppression due to apoptosis. Apoptotic death induced by sunitinib in MCF7 cells was mediated by activation of caspase-3 and p53 mRNA and protein expression and an increase in the percentage of apoptotic cells (40%) as determined by flow cytometry. Apoptosis was associated with a significant inhibition of nuclear factor-kappa B mRNA and protein expression. Mechanistically, blocking of de novo RNA synthesis by actinomycin D significantly inhibited sunitinib-induced expression of p53 mRNA, but not that of caspase-3, indicating involvement of a transcriptional mechanism. This apoptosis-mediated inhibition of MCF7 cell growth was attributed to inhibition of cell cycle-related genes (cyclin D1 and cyclin E2) and arrest of MCF7 cells in the G<sub>2</sub>/M phase in the cell cycle, allowing up-regulation of expression of DNA repair genes such as x-ray repair cross-complementing protein 1. In addition, sunitinib exhibited concentration-dependent induction of oxidative stress genes (heme oxygenase 1 and glutathione transferase A1) through the nuclear factor erythroid 2–related factor 2 pathway. These findings lead us to propose that sunitinib suppressed the proliferation of MCF7 cells via cell-cycle arrest and apoptotic- and oxidative stress-mediated pathways.
refusing Ginkgo
Authors: Richard Donze
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gonococcal tenosynovitis-dermatitis and septic arthritis. Intravenous penicillin vs oral erythromycin
Authors: S. E. Thompson
Journal: JAMA (1980)

Twenty-three patients with disseminated gonococcal infections—15 with acute tenosynovitis, six with septic monoarticular arthritis, and two with both—were randomly given five days of erythromycin stearate or estolate, 500 mg orally every six hours (13 patients), or crystalline aqueous penicillin G potassium, 1 million units intravenously every three hours for three days (ten patients). There were no treatment failures. Cultures taken one and seven days and two and four weeks after completion of therapy were uniformly negative. Clinical resolution was rapid in both groups, as judged by response of fever, joint tenderness, and disappearance of joint effusion. Orally administered erythromycin is a useful alternative to penicillin in the treatment of disseminated gonococcal infections, particularly in penicillinallergic pregnant women. (<i>JAMA</i>244:1101-1102, 1980)
EUTHANASIA.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Table of Contents
Authors: Marie Lafage-Proust, Letizia De Chiara, Paola Romagnani, Mirjam Meissner, Susanne Viehmann, Christian Kurts, Germaine Wong, Wai Lim, Fernando Fervenza, Sanjeev Sethi, George Burke, Alessia Fornoni, Fang Wang, Chao Yang, Jianyan Long, Xinju Zhao, Wen Tang, Dongliang Zhang, Kunhao Bai, Zaiming Su, Bixia Gao, Hong Chu, Jinwei Wang, Xiaoyu Sun, Song Wang, Li Zuo, Yue Wang, Feng Yu, Haibo Wang, Luxia Zhang, Ming-Hui Zhao, Daniela Verzola, Chiara Barisione, Daniela Picciotto, Giacomo Garibotto, Laetitia Koppe, Roisin Connolly, Mark Denton, Hilary Humphreys, Rachel Mcloughlin, Jin Nakamura, Yuki Sato, Yuichiro Kitai, Shuichi Wajima, Shinya Yamamoto, Akiko Oguchi, Ryo Yamada, Keiichi Kaneko, Makiko Kondo, Eiichiro Uchino, Junichi Tsuchida, Keita Hirano, Kumar Sharma, Kenji Kohno, Motoko Yanagita, Chiara Poluzzi, Madalina-Viviana Nastase, Jinyang Zeng-Brouwers, Heiko Roedig, Louise Tzung-Harn Hsieh, Jonas Michaelis, Eva Buhl, Flavia Rezende, Yosif Manavski, André Bleich, Peter Boor, Ralf Brandes, Josef Pfeilschifter, Ernst Stelzer, Christian Münch, Ivan Dikic, Christian Brandts, Renato Iozzo, Malgorzata Wygrecka, Liliana Schaefer, Anne Schijvens, Rasmus Ehren, Lutz Weber, Michiel Schreuder, Gajapathiraju Chamarthi, Abhilash Koratala, Andres Combalia, Ernesto Munoz-Mahamud, Federico Cofan, Mélanie Brunel, Stéphanie Leclerc-Mercier, Jean-Philippe Barnier, Emmanuelle Bille, Rebecca Sberro-Soussan, Christophe Legendre, Anne Scemla
Journal: Kidney International (2019)